123 related articles for article (PubMed ID: 23974492)
1. Metformin inhibits lung cancer cells proliferation through repressing microRNA-222.
Wang Y; Dai W; Chu X; Yang B; Zhao M; Sun Y
Biotechnol Lett; 2013 Dec; 35(12):2013-9. PubMed ID: 23974492
[TBL] [Abstract][Full Text] [Related]
2. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo.
Miyoshi H; Kato K; Iwama H; Maeda E; Sakamoto T; Fujita K; Toyota Y; Tani J; Nomura T; Mimura S; Kobayashi M; Morishita A; Kobara H; Mori H; Yoneyama H; Deguchi A; Himoto T; Kurokohchi K; Okano K; Suzuki Y; Murao K; Masaki T
Int J Oncol; 2014 Jul; 45(1):322-32. PubMed ID: 24806290
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of metformin in esophageal cancer: in vitro study.
Kobayashi M; Kato K; Iwama H; Fujihara S; Nishiyama N; Mimura S; Toyota Y; Nomura T; Nomura K; Tani J; Miyoshi H; Kobara H; Mori H; Murao K; Masaki T
Int J Oncol; 2013 Feb; 42(2):517-24. PubMed ID: 23229592
[TBL] [Abstract][Full Text] [Related]
4. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Ben Sahra I; Laurent K; Loubat A; Giorgetti-Peraldi S; Colosetti P; Auberger P; Tanti JF; Le Marchand-Brustel Y; Bost F
Oncogene; 2008 Jun; 27(25):3576-86. PubMed ID: 18212742
[TBL] [Abstract][Full Text] [Related]
5. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative action of metformin in human lung cancer cell lines.
Ashinuma H; Takiguchi Y; Kitazono S; Kitazono-Saitoh M; Kitamura A; Chiba T; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Iwama A; Yokosuka O; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):8-14. PubMed ID: 22576795
[TBL] [Abstract][Full Text] [Related]
7. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
8. The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
Kato K; Iwama H; Yamashita T; Kobayashi K; Fujihara S; Fujimori T; Kamada H; Kobara H; Masaki T
Oncol Rep; 2016 Mar; 35(3):1582-92. PubMed ID: 26708419
[TBL] [Abstract][Full Text] [Related]
9. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.
Kato K; Gong J; Iwama H; Kitanaka A; Tani J; Miyoshi H; Nomura K; Mimura S; Kobayashi M; Aritomo Y; Kobara H; Mori H; Himoto T; Okano K; Suzuki Y; Murao K; Masaki T
Mol Cancer Ther; 2012 Mar; 11(3):549-60. PubMed ID: 22222629
[TBL] [Abstract][Full Text] [Related]
10. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Horm Metab Res; 2013 May; 45(5):387-90. PubMed ID: 23225247
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo anti-melanoma action of metformin.
Janjetovic K; Harhaji-Trajkovic L; Misirkic-Marjanovic M; Vucicevic L; Stevanovic D; Zogovic N; Sumarac-Dumanovic M; Micic D; Trajkovic V
Eur J Pharmacol; 2011 Oct; 668(3):373-82. PubMed ID: 21806981
[TBL] [Abstract][Full Text] [Related]
12. Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles.
Kumar VB; Yuan TC; Liou JW; Yang CJ; Sung PJ; Weng CF
Mutat Res; 2011 Feb; 707(1-2):42-52. PubMed ID: 21185843
[TBL] [Abstract][Full Text] [Related]
13. Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis.
Tyszka-Czochara M; Konieczny P; Majka M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230778
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells.
Feng YH; Wu CL; Shiau AL; Lee JC; Chang JG; Lu PJ; Tung CL; Feng LY; Huang WT; Tsao CJ
Int J Mol Med; 2012 May; 29(5):920-6. PubMed ID: 22322462
[TBL] [Abstract][Full Text] [Related]
15. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Zakikhani M; Dowling R; Fantus IG; Sonenberg N; Pollak M
Cancer Res; 2006 Nov; 66(21):10269-73. PubMed ID: 17062558
[TBL] [Abstract][Full Text] [Related]
16. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
17. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.
Zang YS; Zhong YF; Fang Z; Li B; An J
Cancer Gene Ther; 2012 Nov; 19(11):773-8. PubMed ID: 22996741
[TBL] [Abstract][Full Text] [Related]
18. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells.
Tosca L; Ramé C; Chabrolle C; Tesseraud S; Dupont J
Reproduction; 2010 Feb; 139(2):409-18. PubMed ID: 19906888
[TBL] [Abstract][Full Text] [Related]
19. Metformin and MiR-365 synergistically promote the apoptosis of gastric cancer cells via MiR-365-PTEN-AMPK axis.
Huang F; Xiang Y; Li T; Huang Y; Wang J; Zhang HM; Li HH; Dai ZT; Li JP; Li H; Zhou J; Liao XH
Pathol Res Pract; 2022 Feb; 230():153740. PubMed ID: 35007850
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
